血必净注射液联合HA330血液灌流对急性脓毒症合并AKI患者的疗效分析
【摘要】目的:分析急性脓毒症合并急性肾损伤(acutekidney injury,AKI)患者实施血必净注射液联合HA330血液灌流的临床疗效。方法:研究回顾性纳入贺州市人民医院2022年6月—2023年11月收治急性脓毒症合并AKI患者83例为对象,依据不同治疗方式将其划分为对照组( n=43 )(常规治疗 + 血液灌流治疗)研究组( n=40 )(血必净注射液联合HA330血液灌流)。比较组间炎症因子[肿瘤坏死因子 -α (tumor necrosis factor- α ,TNF- α)降钙素原(procalcitonin,PCT)及血清白介素-6(interleukin-6,IL-6)]水平,肾功能[血尿素氮(blood urea nitrogen,BUN)、血肌酐(serum creatinine,
)、胱抑素C(cystatinC,CysC)],住院时间,尿量恢复正常时间,腹部压力及肠鸣音次数。结果:治疗前,组间TNF- α 、PCT、IL-6、肾功能指标、腹压水平及肠鸣音次数等指标差异均无统计学意义( Pgt;0.05 );研究组住院时间、尿量恢复正常时间均短于对照组( Plt;0.05 ),治疗7d后,研究组TNF- α PCT、IL-6、BUN、Scr、CysC均低于对照组( Plt;0.05 ),研究组腹压水平低于对照组,肠鸣音次数高于对照组( Plt;0.05 )。结论:血必净注射液联合HA330血液灌流能有效降低急性脓毒症合并AKI患者炎症因子、预后时间,改善肾功能、腹压水平及肠鸣音次数。Analysis of Curative Effect of Xuebijing Injection Combined with HA330 Hemoperfusion in Patients with Acute Sepsis Complicated with AKI/MIAO Jinsong, LI Daiqiang, CHEN Lin. //Medical Innovation of China, 2025, 22(12): 033-037
[Abstract]Objective: To analyze clinical efficacy of Xuebijing Injection complicated with HA330 hemoperfusion in patients with acute sepsis complicated with acute kidney injury (AKI). Method: A total of 83 patients with acute sepsis complicated with AKIadmittedto Hezhou People's Hospitalfrom June2022 to November 2023 were retrospectively included.According to different treatmentmethods ......
您现在查看是摘要页,全文长 13341 字符。